SPA
FENC icon

Sherbrooke Park Advisers’s Fennec Pharmaceuticals FENC Stock Holding History

Sherbrooke Park Advisers’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,742
Closed -$114K – 586
2025
Q2 		$114K Sell
13,742
-4,137
-23% -$28.3K 0.05% 447
2025
Q1 		$109K Sell
17,879
-3,810
-18% -$24.5K 0.05% 500
2024
Q4 		$137K Sell
21,689
-7,941
-27% -$40.7K 0.04% 636
2024
Q3 		$148K Buy
29,630
+1,260
+4% +$7.29K 0.03% 797
2024
Q2 		$173K Buy
+28,370
New +$236K 0.03% 786

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sherbrooke Park Advisers's FENC Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Fennec Pharmaceuticals (FENC) in Q3 2025, closing a stake of 13,742 shares — an estimated $114K sold.

Sherbrooke Park Advisers first reported a position in FENC in Q2 2024 and held it in 5 quarters. The position peaked at $173K in Q2 2024. 84 funds tracked by Wall St. Rank hold FENC as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Fennec Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 13,742 Fennec Pharmaceuticals shares in Q3 2025, an estimated $114K.
  • Sherbrooke Park Advisers first reported a position in Fennec Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Sherbrooke Park Advisers's Fennec Pharmaceuticals position peaked at $173K in Q2 2024.
  • 84 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.